July 12, 2021
GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit
There was a small increase in pCR initially (with no continuity after surgery), questioning the need to maintain immunotherapy as adjuvant treatment, according to data presented in ASCO 2021 During ASCO World Congress […]
July 7, 2021
Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]
July 7, 2021
Given the importance of molecular testing and target therapy for the treatment of metastatic NSCLC, it is essential to understand how testing has been performed in clinical practice […]
July 6, 2021
Camrelizumab and nab-paclitaxel demonstrated promising antitumor activity in immunomodulatory triple-negative metastatic breast cancer (TNBC) patients in FUTURE trial, but the efficacy of adding famitinib to this strategy is under investigation During […]
July 6, 2021
Nivolumab is known to demonstrate significant improvement in disease-free survival versus placebo in patients with resected stage II/III esophageal cancer with residual pathologic disease after neoadjuvant chemoradiotherapy, according to a recent publication in NEJM […]
July 5, 2021
This is the largest real-world analysis of SCLC evaluated by whole transcriptome sequencing The dominant expression of four lineage-defining transcription factors (ASCL1, NEUROD1, YAP1 or POU2F3) allows the classification of small cell […]
July 5, 2021
Patients with HER2+ metastatic breast cancer are at high risk of developing brain metastases and treatment options are limited when secondary involvement lesions arise in the […]
July 2, 2021
Pembrolizumab versus chemotherapy showed progression-free survival improvement in the second provisional analysis in patients with the tumor. The study continued until the final overall survival (OS) analysis, planned after 190 OS events […]
July 2, 2021
The 177Lu-PSMA-617 is a targeted radioligand therapy that distributes ß–particle radiation to cells expressing PSMA and to the surrounding microenvironment During the ASCO World Congress 2021, VISION (NCT03511664), an international, randomized, open-label phase […]